Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Vanda Pharmaceuticals to similar companies based on the strength of its earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and valuation.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Vanda Pharmaceuticals and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vanda Pharmaceuticals | 1 | 2 | 6 | 0 | 2.56 |
| Vanda Pharmaceuticals Competitors | 7845 | 13797 | 25807 | 1039 | 2.41 |
Vanda Pharmaceuticals presently has a consensus target price of $13.50, suggesting a potential upside of 238.35%. As a group, “Pharmaceuticals” companies have a potential upside of 24.24%. Given Vanda Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than its competitors.
Insider and Institutional Ownership
Profitability
This table compares Vanda Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vanda Pharmaceuticals | -119.87% | -62.70% | -37.53% |
| Vanda Pharmaceuticals Competitors | -2,398.26% | -203.62% | -15.08% |
Volatility and Risk
Vanda Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals’ competitors have a beta of -0.04, indicating that their average share price is 104% less volatile than the S&P 500.
Earnings and Valuation
This table compares Vanda Pharmaceuticals and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Vanda Pharmaceuticals | $216.10 million | -$220.47 million | -0.86 |
| Vanda Pharmaceuticals Competitors | $18.54 billion | $3.23 billion | 562.76 |
Vanda Pharmaceuticals’ competitors have higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Vanda Pharmaceuticals beats its competitors on 7 of the 13 factors compared.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders and other conditions. Headquartered in Washington, D.C., the company was founded in 2003. Its commercial products include Fanapt (iloperidone), approved in the United States for schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder, and Hetlioz (tasimelteon), used to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome.
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
